Literature DB >> 19774478

Preparation and evaluation of danofloxacin mesylate microspheres and its pharmacokinetics in pigs.

Chunmei Wang1, Diyun Ai, Cuilan Chen, Heng Lin, Jing Li, Hongchun Shen, Weixue Yi, Yuanhua Qi, Haigang Wu, Jiyue Cao.   

Abstract

Danofloxacin mesylate gelatin microspheres (DFM-GMS) were prepared by an emulsion chemical crosslinking technique. Distribution of particle size, morphologic characteristics, drug content, and drug stability were evaluated. In-vitro study showed that the release of danofloxacin mesylate (DFM) from microspheres was much slower than from the raw material (DFM) in the release medium. Pharmacokinetic characteristics were evaluated following intramuscular injection of DFM-GMS or DFM in pigs at dosage of 2.5 mg/kg body weight. Elimination half-life (t(1/2β)) of the drug was 24.32 h for DFM-GMS, and 6.61 h for DFM (P < 0.01). Overall, DFM-GMS could be applied as a long-acting and lung targeting dosage form of DFM for clinical application.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19774478     DOI: 10.1007/s11259-009-9320-6

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  20 in total

1.  A new oral gelatinized sustained-release dosage form.

Authors:  N TANAKA; S TAKINO; I UTSUMI
Journal:  J Pharm Sci       Date:  1963-07       Impact factor: 3.534

2.  Oxprenolol release from bioadhesive gelatin/poly(acrylic acid) microspheres.

Authors:  S E Leucuta; G Ponchel; D Duchêne
Journal:  J Microencapsul       Date:  1997 Jul-Aug       Impact factor: 3.142

Review 3.  DNA gyrase, topoisomerase IV, and the 4-quinolones.

Authors:  K Drlica; X Zhao
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

4.  Synthesis of gelatin microspheres containing interferon.

Authors:  Y Tabata; Y Ikada
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

5.  Studies on time-kill kinetics of different classes of antibiotics against veterinary pathogenic bacteria including Pasteurella, Actinobacillus and Escherichia coli.

Authors:  L J Norcia; A M Silvia; S F Hayashi
Journal:  J Antibiot (Tokyo)       Date:  1999-01       Impact factor: 2.649

Review 6.  The fluoroquinolone antibacterials: past, present and future perspectives.

Authors:  P C Appelbaum; P A Hunter
Journal:  Int J Antimicrob Agents       Date:  2000-09       Impact factor: 5.283

7.  Pharmacokinetics and pharmacodynamics of danofloxacin in serum and tissue fluids of goats following intravenous and intramuscular administration.

Authors:  F S Aliabadi; P Lees
Journal:  Am J Vet Res       Date:  2001-12       Impact factor: 1.156

8.  Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids.

Authors:  F Shojaee Aliabadi; Badrelin H Ali; M F Landoni; P Lees
Journal:  Vet J       Date:  2003-03       Impact factor: 2.688

9.  Pharmacokinetic-pharmacodynamic integration of danofloxacin in the calf.

Authors:  F Shojaee Aliabadi; P Lees
Journal:  Res Vet Sci       Date:  2003-06       Impact factor: 2.534

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

View more
  4 in total

1.  Susceptibility breakpoint for Danofloxacin against swine Escherichia coli.

Authors:  Yuqi Yang; Yixin Zhang; Jiarui Li; Ping Cheng; Tianshi Xiao; Ishfaq Muhammad; Hongxiao Yu; Ruimeng Liu; Xiuying Zhang
Journal:  BMC Vet Res       Date:  2019-02-04       Impact factor: 2.741

2.  Pharmacokinetics and pharmacodynamics integration of danofloxacin against Eschrichia coli in piglet ileum ultrafiltration probe model.

Authors:  Yuqi Yang; Ping Cheng; Tianshi Xiao; Jargalsaikhan Ulziikhutag; Hongxiao Yu; Jiarui Li; Ruimeng Liu; Ishfaq Muhammad; Xiuying Zhang
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

3.  Comparison of PK/PD Targets and Cutoff Values for Danofloxacin Against Pasteurella multocida and Haemophilus parasuis in Piglets.

Authors:  Yu-Feng Zhou; Zhen Sun; Rui-Ling Wang; Jian-Guo Li; Chao-Yan Niu; Xian-An Li; Yun-Yun Feng; Jian Sun; Ya-Hong Liu; Xiao-Ping Liao
Journal:  Front Vet Sci       Date:  2022-02-02

4.  Analysis of the mutant selection window and killing of Mycoplasma hyopneumoniae for doxycycline, tylosin, danofloxacin, tiamulin, and valnemulin.

Authors:  Zilong Huang; Chunxiao Mao; Yanzhe Wei; Xiaoyan Gu; Qinren Cai; Xiangguang Shen; Huanzhong Ding
Journal:  PLoS One       Date:  2020-06-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.